BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10413273)

  • 1. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial.
    Klumpp TR; Herman JH; Gaughan JP; Russo RR; Christman RA; Goldberg SL; Ackerman SJ; Bleecker GC; Mangan KF
    Transfusion; 1999 Jul; 39(7):674-81. PubMed ID: 10413273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation--a prospective analysis.
    Ishida A; Handa M; Wakui M; Okamoto S; Kamakura M; Ikeda Y
    Transfusion; 1998 Sep; 38(9):839-47. PubMed ID: 9738624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts.
    Adkins D; Spitzer G; Johnston M; Velasquez W; Dunphy F; Petruska P
    Transfusion; 1997 Jul; 37(7):737-48. PubMed ID: 9225939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
    Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
    Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.
    Messerschmidt GL; Makuch R; Appelbaum F; Ungerleider RS; Abrams R; O'Donnell J; Holohan TV; Fontana J; Wright D; Anagnou NP
    Cancer; 1988 Aug; 62(4):795-801. PubMed ID: 3293762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials.
    Cid J; Lozano M
    Transfusion; 2007 Mar; 47(3):464-70. PubMed ID: 17319827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.
    Goodnough LT; Kuter DJ; McCullough J; Slichter SJ; DiPersio J; Romo J; Peterson R; Smith KJ; Raife T; Tomita D; Armstrong S
    Blood; 2001 Sep; 98(5):1346-51. PubMed ID: 11520781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger.
    Zumberg MS; del Rosario ML; Nejame CF; Pollock BH; Garzarella L; Kao KJ; Lottenberg R; Wingard JR
    Biol Blood Marrow Transplant; 2002; 8(10):569-76. PubMed ID: 12434952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet transfusion: a dose-response study.
    Norol F; Bierling P; Roudot-Thoraval F; Le Coeur FF; Rieux C; Lavaux A; Kuentz M; Duedari N
    Blood; 1998 Aug; 92(4):1448-53. PubMed ID: 9694735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogen-reduced platelets for the prevention of bleeding.
    Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
    Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
    Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of platelet transfusion triggers in a tertiary-care hospital.
    Cameron B; Rock G; Olberg B; Neurath D
    Transfusion; 2007 Feb; 47(2):206-11. PubMed ID: 17302765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
    Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
    Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia.
    Wandt H; Frank M; Ehninger G; Schneider C; Brack N; Daoud A; Fackler-Schwalbe I; Fischer J; Gäckle R; Geer T; Harms P; Löffler B; Ohl S; Otremba B; Raab M; Schönrock-Nabulsi P; Strobel G; Winter R; Link H
    Blood; 1998 May; 91(10):3601-6. PubMed ID: 9572994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial.
    Marsh JC; Stanworth SJ; Pankhurst LA; Kallon D; Gilbertson AZ; Pigden C; Deary AJ; Mora AS; Brown J; Laing ES; Choo LL; Hodge R; Llewelyn CA; Harding K; Sage D; Mijovic A; Mufti GJ; Navarrete CV; Brown CJ
    Blood; 2021 Jan; 137(3):310-322. PubMed ID: 33475737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the rate of reduction in platelet counts in recipients of hematopoietic stem and progenitor cell transplant: clinical implications for platelet transfusion therapy.
    del Rosario ML; Kao KI
    Transfusion; 1997; 37(11-12):1163-8. PubMed ID: 9426640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients.
    Diedrich B; Remberger M; Shanwell A; Svahn BM; Ringdén O
    Transfusion; 2005 Jul; 45(7):1064-72. PubMed ID: 15987349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triggers for prophylactic use of platelet transfusions and optimal platelet dosing in thrombocytopenic dogs and cats.
    Abrams-Ogg AC
    Vet Clin North Am Small Anim Pract; 2003 Nov; 33(6):1401-18. PubMed ID: 14664205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses.
    Arnold DM; Crowther MA; Cook RJ; Sigouin C; Heddle NM; Molnar L; Cook DJ
    Transfusion; 2006 Aug; 46(8):1286-91. PubMed ID: 16934061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.